-transparent.png){kind=logo}
Classic features of thyrotoxicosis developed in three patients with no prior history of thyroid disease shortly after the discontinuation of therapy with or decrease in doseage of propranolol hydrochloride. Graves' disease probably developed fortuitously after propranolol therapy was instituted, but the beta-adrenergic blockade masked the clinical features of hyperthyroidism. On discontinuation of propranolol therapy or decrease in propranolol dosage, previously latent thyrotoxicosis became manifest. If hyperthyroidism masked by beta-blockade is not recognized before withdrawal of propranolol therapy in patients with ischemic heart disease, the sudden appearance of thyrotoxicosis may lead to symptoms of increased myocardial ischemia.
L Shenkman, and
P Podrid, and
J Lowenstein
August 1974,
American heart journal,
L Shenkman, and
P Podrid, and
J Lowenstein
December 1986,
The American journal of psychiatry,
L Shenkman, and
P Podrid, and
J Lowenstein
September 1974,
The Journal of thoracic and cardiovascular surgery,
L Shenkman, and
P Podrid, and
J Lowenstein
August 1978,
Annals of internal medicine,
L Shenkman, and
P Podrid, and
J Lowenstein
October 1968,
Lancet (London, England),
L Shenkman, and
P Podrid, and
J Lowenstein
January 1968,
Drug and therapeutics bulletin,
L Shenkman, and
P Podrid, and
J Lowenstein
March 1972,
Postgraduate medicine,
L Shenkman, and
P Podrid, and
J Lowenstein
November 1974,
Annals of internal medicine,
L Shenkman, and
P Podrid, and
J Lowenstein
December 1975,
Circulation,
L Shenkman, and
P Podrid, and
J Lowenstein
January 1995,
La Revue de medecine interne,
